Glurenorm

Glurenorm is a prescription medication that contains the active ingredient gliquidone. It is formulated for oral administration, though the specific dosage form and strength are not disclosed. Classified as a sulfonylurea, Glurenorm belongs to the antidiabetic (oral hypoglycemic) therapeutic class and is marketed within the European Union. It works by stimulating insulin release from pancreatic beta‑cells to help manage blood glucose levels.

Glurenorm is indicated for the management of type 2 diabetes mellitus in adults. It may be used as part of a comprehensive diabetes treatment plan that includes diet, exercise, and other glucose‑lowering agents.

- Improves glycemic control in patients with insufficient response to diet and exercise alone. - Can be combined with metformin or other oral antidiabetic drugs when monotherapy is inadequate. - May be considered for patients who require an alternative to other sulfonylureas due to tolerability. - Used under physician supervision to achieve target HbA1c levels. - Suitable for patients with stable renal function when dosage is appropriately adjusted.

Glurenorm may cause a range of side effects, some of which are more frequently observed than others.

Common: - Mild hypoglycemia, especially when meals are skipped. - Gastrointestinal discomfort such as nausea or abdominal pain. - Headache or dizziness. - Skin rash or mild itching. - Weight gain due to increased insulin activity.

Serious: - Severe hypoglycemia leading to confusion, loss of consciousness, or seizures. - Allergic reactions including swelling of the face, lips, or throat. - Hepatotoxicity presenting as jaundice or elevated liver enzymes. - Hematologic abnormalities such as leukopenia or thrombocytopenia. - Pancreatitis with abdominal pain and elevated pancreatic enzymes.

Before initiating Glurenorm, certain precautions should be considered to ensure safe use.

- Assess renal and hepatic function; dose adjustments may be required in impairment. - Monitor blood glucose regularly to detect hypoglycemia early. - Use cautiously in elderly patients who may be more susceptible to low blood sugar. - Evaluate for a history of cardiovascular disease, as sulfonylureas can affect cardiac outcomes. - Avoid use during pregnancy or lactation unless clearly indicated by a healthcare professional. - Discontinue if signs of severe allergic reaction or liver dysfunction appear.

Glurenorm can interact with several medications, influencing its efficacy or safety profile.

Avoid: - Concurrent use with other sulfonylureas or insulin, which may cause profound hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can increase gliquidone plasma levels. - Certain non‑steroidal anti‑inflammatory drugs (NSAIDs) that may potentiate hypoglycemic effects.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Thiazide diuretics, as they can affect glucose metabolism. - Alcohol, which may enhance the risk of hypoglycemia. - Oral contraceptives, potentially altering glycemic control.